Bioequivalence Study of Amoxicillin 400 mg/Clavulanic Acid 57 mg Chewable Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2002-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to compare the single-dose relative bioavailability of
Ranbaxy and GlaxoSmithKline (Augmentin®) 400 mg amoxicillin (as the trihydrate) and 57 mg
clavulnic acid (as the potassium salt) chewable tablet, following administration of 2 tablet
dose under fasting conditions